Neurocrine Biosciences

American biopharmaceutical company

NBIX Nasdaq ISIN US64125C1099 SEC CIK 914475 LEI 549300FECER0XBN49756
Follow Neurocrine Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.1B +41.2% vs same quarter last year
Net income $206.5M −1.4% vs same quarter last year
EPS, diluted $1.96 −3.9% vs same quarter last year
Operating cash flow $395.2M +73.7% vs same quarter last year
Revenue by quarter
$627.7M
$572.6M
$687.5M
$794.9M
$805.5M
$814.5M
$959M
$1.1B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B$0$1B$2B$3BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$2.9B$478.6M
FY24$2.4B$341.3M
FY23$1.9B$249.7M
FY22$1.5B$154.5M
FY21$1.1B$89.6M
FY20$1B$407.3M
FY19$788.1M$37M
FY18$451.2M$21.1M
FY17$161.6M−$142.5M
FY16$15M−$141.1M
FY15$19.8M−$88.9M
FY14$0−$60.5M
FY13$2.9M−$46.1M
FY12$53.1M$5M
FY11$77.4M$37.6M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2598.2%21.6%16.7%
FY2498.6%24.2%14.5%
FY2397.9%13.3%13.2%
FY2298.4%16.7%10.4%
FY2198.7%9%7.9%
FY2099%15.6%38.9%
FY19-9.2%4.7%
FY1898.9%8.2%4.7%
FY1799.2%−81.3%−88.2%
FY16100%−982.5%−940.6%
FY15100%−476.5%−449.8%
FY14---
FY13-−1701.9%−1579%
FY12-2.7%9.5%
FY11-43.8%48.5%
Free cash flowOperating cash flow minus capital expenditure
−$250M$0$250M$500M$750MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$748.7M
FY24$557.2M
FY23$361.6M
FY22$322.9M
FY21$233.1M
FY20$217.6M
FY19$132.3M
FY18$76.6M
FY17−$101.3M
FY16−$110.3M
FY15−$39.9M
FY14−$48.8M
FY13−$30.2M
FY12−$36.3M
FY11−$1.4M
Returned to shareholdersDividends paid and shares bought back
$0$100M$200M$300MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$167.7M
FY24$300M
FY23$0
FY22$0
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Neurocrine Biosciences
  • Healthcare median
−2000%−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNeurocrine BiosciencesHealthcare median
FY2516.7%−30.6%
FY2414.5%−47%
FY2313.2%−58%
FY2210.4%−80.4%
FY217.9%−71.9%
FY2038.9%−62.2%
FY194.7%−46.3%
FY184.7%−49.6%
FY17−88.2%−45.9%
FY16−940.6%−36%
FY15−449.8%−38.4%
FY14-−35.5%
FY13−1579%−37.1%
FY129.5%−29.1%
FY1148.5%−27.9%